How to diagnose NAFLD in 2016

(1)

How to diagnose NAFLD in 2016

E. Bugianesi1_{, C. Rosso}1_{, H. Cortez-Pinto}2

1_{Division of Gastroenterology, Department of Medical Sciences, A.O.U. Città della} Salute e della Scienza di Torino, University of Torino, Italy

2_{Department of Gastroenterology, Hospital de Santa Maria, CHLN, Laboratory of}

Nutrition, Faculty of Medicine of Lisbon, University of Lisbon, Portugal Address for correspondence:

Department of Medical Sciences University of Torino

A.O.U. Città della Salute e della Scienza Corso Dogliotti 14

10126 Torino, Italy References

1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol. 2016; 64:1388– 14022.

2. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209-1222.

3. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015;149:389-397 e310.

4. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.

5. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, et al. Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2013; 145:782–789.

6. Liu YL, Patman GL, Leahart JB, Piquet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs 738409C>G confers an increased risk of of non-alcoholic associated hepatocellular carcinoma. J Hepatol 2014; 61: 75-81.

7. Sanyal A, Brunt E, KleinerK, Kowdley V, Chalasani, Lavine JE, Ratziu V, McCullough A. Endpoints for clinical trial design for Nonalcoholic steatohepatitis. Hepatology 2011; 54:344-353

8. Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis,

(2)

activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60:565–575